| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB600-1071SS | |||
| Azide and BSA Free | NBP2-80642 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB110-89726SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-47386SS | |||
| Azide and BSA Free | NBP2-80650 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-654SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-22114SS | |||
| Azide and BSA Free | NBP2-80827 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB600-985-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-65543SS | |||
| Azide and BSA Free | NBP2-80661 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-724SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-725SS | |||
![Immunocytochemistry/Immunofluorescence: CD34 Antibody (MEC 14.7) [NB600-1071] - CD34 antibody was tested in WEHI-3 cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red).](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Immunocytochemistry-Immunofluorescence-NB600-1071-img0003.jpg)
![Immunohistochemistry-Paraffin: CD34 Antibody (MEC 14.7) [NB600-1071] - Analysis of a FFPE tissue section of mouse small intestine using rat anti-mouse CD34 (clone MEC 14.7) at 1:100 dilution. The signal was developed using HRP-conjugated anti-rat secondary with DAB reagent which followed counterstaining of nuclei using hematoxylin. This antibody specifically labelled the endothelial cells in blood vessels located primarily in the sub-mucosa, and of that of the mucosa muscularis and the mucosal lacteal.](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Immunohistochemistry-Paraffin-NB600-1071-img0014.jpg)
![Flow Cytometry: CD34 Antibody (MEC 14.7) [NB600-1071] - CD34 (MEC 14.7) antibody was tested at 1:250 in WEHI-3 cells with DyLight 488 (green) alongside a matched isotype control (black).](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Flow-Cytometry-NB600-1071-img0002.jpg)
![Immunohistochemistry-Paraffin: CD34 Antibody (MEC 14.7) [NB600-1071] - Analysis of CD34 on human renal cancer xenograft using CD34 antibody (clone MEC 14.7). The antibody detected the endothelial cells in the tumor vasculature which are originating from the host (mouse).](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Immunohistochemistry-Paraffin-NB600-1071-img0005.jpg)
![Immunohistochemistry-Paraffin: CD34 Antibody (MEC 14.7) [NB600-1071] - Analysis of a human renal cancer tissue section using CD34 antibody (clone MEC 14.7) at 1:100 dilution. The antibody did not detect human CD34 which is an expected outcome for this clone. This section was included in NB600-1071's IHC validation testing as a negative control.](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Immunohistochemistry-Paraffin-NB600-1071-img0006.jpg)
![Immunohistochemistry-Paraffin: CD34 Antibody (MEC 14.7) [NB600-1071] - Analysis of a FFPE tissue section of human renal cancer xenograft using CD34 antibody clone MEC 14.7 at 1:100 dilution. The signal was developed using HRP-conjugated secondary antibody and DAB reagent followed by counterstaining of nuclei with hematoxylin. Notably, the antibody specifically stained the endothelial cells of the tumor vasculature which is originating from the host animal cells (mouse). This observation was verified by including a negative control in this validation testing (see the IHC image of human renal cancer tissue section with negative signal for CD34).](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Immunohistochemistry-Paraffin-NB600-1071-img0009.jpg)
![Immunohistochemistry-Paraffin: CD34 Antibody (MEC 14.7) [NB600-1071] - Analysis of a FFPE tissue section of human renal cancer xenograft using CD34 antibody (clone MEC 14.7) at 1:100 dilution. The staining was detected using HRP-conjugated secondary antibody and DAB reagent followed by counterstaining of nuclei with hematoxylin. Note that this murine CD34 specific antibody stained only the endothelial cells of the tumor vasculature which is originating from the host animal cells (mouse). This observation was verified by including a negative control in this validation testing (see the IHC image of human renal cancer tissue section with negative signal for CD34).](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Immunohistochemistry-Paraffin-NB600-1071-img0010.jpg)
![Immunohistochemistry-Paraffin: CD34 Antibody (MEC 14.7) [NB600-1071] - Analysis of a FFPE tissue section of mouse colon using rat anti-mouse CD34 (clone MEC 14.7) at 1:100 dilution. The signal was developed using HRP-conjugated anti-rat secondary with DAB reagent which followed counterstaining of nuclei using hematoxylin. The antibody specifically generated a staining of the endothelial cells in blood vessels of the colon.](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Immunohistochemistry-Paraffin-NB600-1071-img0012.jpg)
![Immunohistochemistry-Paraffin: CD34 Antibody (MEC 14.7) [NB600-1071] - Analysis of a FFPE tissue section of mouse heart using rat anti-mouse CD34 (clone MEC 14.7) at 1:100 dilution. The signal was developed using HRP-conjugated anti-rat secondary with DAB reagent which followed counterstaining of nuclei using hematoxylin. The antibody specifically generated a staining of the endothelial cells in blood vessels of the heart tissue.](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Immunohistochemistry-Paraffin-NB600-1071-img0013.jpg)
![Flow Cytometry: CD34 Antibody (MEC 14.7) [NB600-1071] - An intracellular stain was performed on Raw264.7 cells with CD34 Antibody [MEC 14.7] NB600-1071 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rat IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 488 (SA5-10018, Thermo Fisher).](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Flow-Cytometry-NB600-1071-img0015.jpg)
![Western Blot: S100A9 Antibody [NB110-89726] - Cells were transfected with the pCMV6-ENTRY S100A9 cDNA or the pCMV6-ENTRY control for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-S100A9.](http://images.novusbio.com/fullsize/S100A9-Antibody-Western-Blot-NB110-89726-img0007.jpg "Western Blot: S100A9 Antibody [NB110-89726] - Cells were transfected with the pCMV6-ENTRY S100A9 cDNA or the pCMV6-ENTRY control for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-S100A9.")
![Immunocytochemistry/Immunofluorescence: S100A9 Antibody [NB110-89726] - S100A9 antibody was tested in A431 cells with FITC (green). Nuclei and alpha-tubulin were counterstained with Dapi (blue) and Dylight 550 (red).](http://images.novusbio.com/fullsize/S100A9-Antibody-Immunocytochemistry-Immunofluorescence-NB110-89726-img0008.jpg)
![Immunohistochemistry-Paraffin: S100A9 Antibody [NB110-89726] - Key molecules of specific signaling pathways are assayed by immunohistochemistry in the colorectum of mice. Immunohistochemistry (200x magnification) of S100a9, in normal control, IgG Ab, and anti-S100a9 Ab-treated colorectal tissues of the colitis-associated cancer mouse (n = 4). Scale bar, 50 um. Staining scores were determined by semi-quantitative optical analysis. Image collected and cropped by CiteAb from the following publication (//journal.frontiersin.org/article/10.3389/fimmu.2017.01774/full), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/S100A9-Antibody-Immunohistochemistry-Paraffin-NB110-89726-img0010.jpg)
![Western Blot: S100A9 Antibody [NB110-89726] - Analysis of S100A9 Antibody in DMSO treated HL60 whole cell lysates.](http://images.novusbio.com/fullsize/S100A9-Antibody-Western-Blot-NB110-89726-img0006.jpg)
![Simple Western: S100A9 Antibody [NB110-89726] - Simple Western lane view shows a specific band for S100A9 in 0.5 mg/ml of Human PBMC's lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/S100A9-Antibody-Simple-Western-NB110-89726-img0009.jpg)
![Immunohistochemistry: S100A9 Antibody [NB110-89726] - Key molecules of specific signaling pathways are assayed by immunohistochemistry in the colorectum of mice. Immunohistochemistry (200× magnification) of (A) S100a9, (B) beta -catenin, (C) c-Myc, (D) p-Akt, (E) p-Smad2, & (F) Cxcl5 in normal control, IgG Ab, & anti-S100a9 Ab-treated colorectal tissues of the colitis-associated cancer mouse (n = 4). Scale bar, 50 µm. Staining scores were determined by semi-quantitative optical analysis. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29326691), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-89726_rabbit-polyclonal-s100a9-antibody-310202415291935.jpg)
![Immunohistochemistry: S100A9 Antibody [NB110-89726] - Key molecules of specific signaling pathways are assayed by immunohistochemistry in the colorectum of mice. Immunohistochemistry (200× magnification) of (A) S100a9, (B) beta -catenin, (C) c-Myc, (D) p-Akt, (E) p-Smad2, & (F) Cxcl5 in normal control, IgG Ab, & anti-S100a9 Ab-treated colorectal tissues of the colitis-associated cancer mouse (n = 4). Scale bar, 50 µm. Staining scores were determined by semi-quantitative optical analysis. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29326691), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-89726_rabbit-polyclonal-s100a9-antibody-310202415371968.jpg)
![Immunohistochemistry: S100A9 Antibody [NB110-89726] - Key molecules of specific signaling pathways are assayed by immunohistochemistry in the colorectum of mice. Immunohistochemistry (200× magnification) of (A) S100a9, (B) beta -catenin, (C) c-Myc, (D) p-Akt, (E) p-Smad2, & (F) Cxcl5 in normal control, IgG Ab, & anti-S100a9 Ab-treated colorectal tissues of the colitis-associated cancer mouse (n = 4). Scale bar, 50 µm. Staining scores were determined by semi-quantitative optical analysis. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29326691), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-89726_rabbit-polyclonal-s100a9-antibody-310202415395938.jpg)
![Immunohistochemistry: S100A9 Antibody [NB110-89726] - Key molecules of specific signaling pathways are assayed by immunohistochemistry in the colorectum of mice. Immunohistochemistry (200× magnification) of (A) S100a9, (B) beta -catenin, (C) c-Myc, (D) p-Akt, (E) p-Smad2, & (F) Cxcl5 in normal control, IgG Ab, & anti-S100a9 Ab-treated colorectal tissues of the colitis-associated cancer mouse (n = 4). Scale bar, 50 µm. Staining scores were determined by semi-quantitative optical analysis. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29326691), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-89726_rabbit-polyclonal-s100a9-antibody-31020241539727.jpg)
![Immunohistochemistry: S100A9 Antibody [NB110-89726] - Key molecules of specific signaling pathways are assayed by immunohistochemistry in the colorectum of mice. Immunohistochemistry (200× magnification) of (A) S100a9, (B) beta -catenin, (C) c-Myc, (D) p-Akt, (E) p-Smad2, & (F) Cxcl5 in normal control, IgG Ab, & anti-S100a9 Ab-treated colorectal tissues of the colitis-associated cancer mouse (n = 4). Scale bar, 50 µm. Staining scores were determined by semi-quantitative optical analysis. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29326691), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-89726_rabbit-polyclonal-s100a9-antibody-31020241529199.jpg)
![Immunohistochemistry: S100A9 Antibody [NB110-89726] - Effects of anti-S100a9 Ab administration on the azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colitis-associated cancer development. (A) Experimental procedure of the control group & the AOM/DSS group treated with IgG Ab or anti-S100a9 Ab. (B) DAI of the IgG Ab or anti-S100a9 Ab-treated AOM/DSS mice & normal controls. (C) General observation of the colorectums in mice at the end of the 13th & 18th week. (D) Colon length, tumor rate, & number of macroscopic neoplasms were statisticed at 13 & 18 weeks, individually. n = 5–9 per group. Results were representative of the three experiments performed. (E) Histopathological examination of colon sections was shown under the Pannoramic Viewer (H&E staining, upper panels: original magnification 10×, scale bar: 2000 µm; lower panels: original magnification 200×, scale bar: 100 µm). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29326691), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-89726_rabbit-polyclonal-s100a9-antibody-310202416205192.jpg)
![Immunohistochemistry: S100A9 Antibody [NB110-89726] - Effects of anti-S100a9 Ab on the frequency of neutrophils, macrophages, & dendritic cells (DCs) in the colon of the dextran sulfate sodium (DSS) mouse model. (A) Colon lamina propria cells were isolated from normal control & IgG Ab or anti-S100a9 Ab-treated DSS mice at day 6 post-DSS colitis induction. Frequencies of neutrophils, macrophages, & DCs in the colon were determined by flow cytometry. Cells were gated on CD45+CD3−CD4−CD11b+Ly6G+, CD45+CD3−CD4−CD11b+F4/80+, & CD45+CD3−CD4−CD11b+CD11c+ populations respectively. Representative flow cytometric figures were shown. The percentage of cells was presented as the mean ± SEM of four to six individual mice per group. *p < 0.05 in a one-way analysis of variance followed by Bonferroni correction. Data were representative of three independent experiments. (B) Immunohistochemical staining of myeloperoxidase (MPO), CD68, & CD11c proteins in the normal control & IgG Ab or anti-S100a9 Ab-treated colitis mice at day 6 (left panels: original magnification 40×, scale bar: 200 µm; right panels: original magnification 200×, scale bar: 50 µm). Staining scores were counted. One-way analysis of variance followed by Bonferroni correction. Results were representative of the three experiments performed. Error bars represent SD. (C) Expression of S100a9, Tnf alpha , Il1 beta , Il6, Il17a, Ifn gamma , Il12a, Il23a, Il4, & Il10 mRNA, as assessed by quantitative real-time PCR in normal control & IgG Ab, or anti-S100a9 Ab-treated colitis tissues. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29326691), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-89726_rabbit-polyclonal-s100a9-antibody-310202416205114.jpg)
![Immunohistochemistry: S100A9 Antibody [NB110-89726] - Anti-S100a9 Ab ameliorates inflammatory response of dextran sulfate sodium (DSS)-induced colitis in mice. (A) 6 days after DSS treatment, representative H&E-stained colon sections were shown (upper panels: original magnification 40×, scale bar: 200 µm; lower panels: original magnification 100×, scale bar: 100 µm). (B) Colon inflammation, ulceration, & crypt damage were scored individually, & composite total score was scored. n = 5 per group. (C) Isolated lymphoid follicles (ILFs) area was measured at day 6. Representative TUNEL staining (D) & ethynyl-2′-deoxyuridine (EdU) staining (E) of normal mice & DSS-induced mice, which were treated with IgG Ab or anti-S100a9 Ab on day 6. The percent of positive cells was measured. At least six fields were counted per mouse. Scale bar, 100 µm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29326691), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-89726_rabbit-polyclonal-s100a9-antibody-31020241621842.jpg)
![Immunohistochemistry: S100A9 Antibody [NB110-89726] - Host CP (S100A8/A9) is elevated in H. pylori infected stomach tissue.A) s100a8/s100a9 transcript abundance in RNA extracted from C57BL/6 mice infected with H. pylori PMSS1 or SS1 for 1, 2, or 3 months relative to uninfected animals as determined by real-time RT-PCR analysis. Points indicate mean relative units of transcript abundance +/− SEM (levels of s100a8 in PMSS1-infected mice compared to uninfected mice; 1 mo p = 0.0511; 2 mo p = 0.0432; 3 mo p = 0.0127; levels of s100a8 in SS1-infected mice compared to uninfected mice at 2 mo p = 0.0623 Student's t test). (B) Inflammation scores of H. pylori infected mice at 1, 2, & 3 months post infection. (C) s100a8/s100a9 transcript abundance in RNA extracted from gastric biopsies derived from human patients, which were either H. pylori-positive or H. pylori-negative (s100a8 p = 0.15; s100a9 *p = 0.05). Bars indicate mean relative units of transcript abundance +/− SEM. Each experimental group represents≥5 individuals (mice or human samples). D) Gastric samples derived from H. pylori PMSS1-infected WT mice or SS1-infected WT mice at 2 months post-infection were analyzed via immunohistochemistry using a polyclonal antibody to S100A9 (scale bars are 50 microns). E) Real-time RT-PCR was performed on gastric tissue to quantify s100a8 & s100a9 transcript abundance from WT (C57BL/6 mice) & IL-17RA-/- mice infected with PMSS1. Data represent relative units of transcript abundance +/− SEM in WT mice & IL-17RA-/- mice, *p = 0.0169 & p = 0.0143, respectively. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25330071), licensed under a CC0-1.0 license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-89726_rabbit-polyclonal-s100a9-antibody-310202416205130.jpg)
![Immunohistochemistry: S100A9 Antibody [NB110-89726] - Anti-S100a9 Ab ameliorates inflammatory response of dextran sulfate sodium (DSS)-induced colitis in mice. (A) 6 days after DSS treatment, representative H&E-stained colon sections were shown (upper panels: original magnification 40×, scale bar: 200 µm; lower panels: original magnification 100×, scale bar: 100 µm). (B) Colon inflammation, ulceration, & crypt damage were scored individually, & composite total score was scored. n = 5 per group. (C) Isolated lymphoid follicles (ILFs) area was measured at day 6. Representative TUNEL staining (D) & ethynyl-2′-deoxyuridine (EdU) staining (E) of normal mice & DSS-induced mice, which were treated with IgG Ab or anti-S100a9 Ab on day 6. The percent of positive cells was measured. At least six fields were counted per mouse. Scale bar, 100 µm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29326691), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-89726_rabbit-polyclonal-s100a9-antibody-310202416205132.jpg)
![Immunohistochemistry: S100A9 Antibody [NB110-89726] - Anti-S100a9 Ab ameliorates inflammatory response of dextran sulfate sodium (DSS)-induced colitis in mice. (A) 6 days after DSS treatment, representative H&E-stained colon sections were shown (upper panels: original magnification 40×, scale bar: 200 µm; lower panels: original magnification 100×, scale bar: 100 µm). (B) Colon inflammation, ulceration, & crypt damage were scored individually, & composite total score was scored. n = 5 per group. (C) Isolated lymphoid follicles (ILFs) area was measured at day 6. Representative TUNEL staining (D) & ethynyl-2′-deoxyuridine (EdU) staining (E) of normal mice & DSS-induced mice, which were treated with IgG Ab or anti-S100a9 Ab on day 6. The percent of positive cells was measured. At least six fields were counted per mouse. Scale bar, 100 µm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29326691), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-89726_rabbit-polyclonal-s100a9-antibody-310202416205144.jpg)
![Immunocytochemistry/Immunofluorescence: CD44 Antibody (8E2F3) [NBP1-47386] - Analysis of paraffin-embedded human lung cancer tissues using anti-CD44 mAb (green), showing membrane localization. DRAQ5 fluorescent DNA dye (blue).](http://images.novusbio.com/fullsize/CD44-Antibody-8E2F3-Immunocytochemistry-Immunofluorescence-NBP1-47386-img0011.jpg "Immunocytochemistry/Immunofluorescence: CD44 Antibody (8E2F3) [NBP1-47386] - Analysis of paraffin-embedded human lung cancer tissues using anti-CD44 mAb (green), showing membrane localization. DRAQ5 fluorescent DNA dye (blue).")
![Immunohistochemistry-Paraffin: CD44 Antibody (8E2F3) [NBP1-47386] - Analysis of FFPE human breast carcinoma tissues using CD44 antibody (8E2F3). The signal was developed using DAB based detection and the sections were processed for counterstaining with hematoxylin. The antibody generated mainly a membrane staining representative of CD44 protein.](http://images.novusbio.com/fullsize/CD44-Antibody-8E2F3-Immunohistochemistry-Paraffin-NBP1-47386-img0014.jpg)
![Flow Cytometry: CD44 Antibody (8E2F3) [NBP1-47386] - Analysis of HeLa cells using anti-CD44 mAb (right) and negative control (left).](http://images.novusbio.com/fullsize/CD44-Antibody-8E2F3-Flow-Cytometry-NBP1-47386-img0008.jpg)
![Immunocytochemistry/Immunofluorescence: CD44 Antibody (8E2F3) [NBP1-47386] - HeLa cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-CD44 Antibody [8E2F3] conjugated to DyLight 550 (NBP1-47386R) at 5 ug/ml for 1 hour at room temperature. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/CD44-Antibody-8E2F3-Immunocytochemistry-Immunofluorescence-NBP1-47386-img0018.jpg)
![Western Blot: CD44 Antibody (8E2F3) - BSA Free [NBP1-47386] - Generation and characterization of immortalized primary keratinocytes (IPKs) from K14Cre.Ptpn2w/w and K14Cre.Ptpn2fl/fl mice. Western blot analysis of pSTAT3, STAT3, and CD44 (NBP1-47386) in primary keratinocytes and IPKs from both genotypes. The A431 cells were used as positive controls. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29955047/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD44-Antibody-8E2F3-BSA-Free-Western-Blot-NBP1-47386-img0021.jpg)
![Immunocytochemistry/Immunofluorescence: CD44 Antibody (8E2F3) [NBP1-47386] - HeLa cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with CD44 Antibody [8E2F3] conjugated to Alexa Fluor 647 (NBP1-47386AF647) at 5 ug/ml for 1 hour at room temperature. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/CD44-Antibody-8E2F3-Immunocytochemistry-Immunofluorescence-NBP1-47386-img0019.jpg)
![Flow Cytometry: CD44 Antibody (8E2F3) [NBP1-47386] - An intracellular stain was performed on HeLa cells with NBP1-47386AF488 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.](http://images.novusbio.com/fullsize/CD44-Antibody-8E2F3-Flow-Cytometry-NBP1-47386-img0017.jpg)
![Immunocytochemistry/Immunofluorescence: CD44 Antibody (8E2F3) [NBP1-47386] - Analysis of methanol-fixed A431 (A), HeLa (B), PANC-1 (C) and EC (D) cells using anti-CD44 mAb (green), showing membrane localization. DRAQ5 fluorescent DNA dye (blue).](http://images.novusbio.com/fullsize/CD44-Antibody-8E2F3-Immunocytochemistry-Immunofluorescence-NBP1-47386-img0009.jpg)
![Immunocytochemistry/Immunofluorescence: CD44 Antibody (8E2F3) [NBP1-47386] - Analysis of PANC-1 cells using anti-CD44 mAb (green). Actin filaments have been labeled with DY-554 phalloidin (red). DRAQ5 fluorescent DNA dye (blue).](http://images.novusbio.com/fullsize/CD44-Antibody-8E2F3-Immunocytochemistry-Immunofluorescence-NBP1-47386-img0010.jpg)
![Flow (Intracellular): CD44 Antibody (8E2F3) [NBP1-47386] - An intracellular stain was performed on HeLa cells with NBP1-47386AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/CD44-Antibody-8E2F3-Flow-Intracellular-NBP1-47386-img0016.jpg)
![Immunoprecipitation: CD44 Antibody (8E2F3) - BSA Free [NBP1-47386] - HAP1 lysates were prepared and immunoprecipitation was performed using 1.0 ug of the CD44 Antibody (NBP1-47386) pre-coupled to either protein G or protein A Sepharose beads. Ability of the antibodies to capture CD44 antigen was first assessed by comparing the level of CD44 antigen from the starting material (SM) to its level remaining in the unbound fractions (UB). Anti-CD44 antigen at 1/2000 was used for each immunoblot. Immunoprecipitate for CD44 Antibody (NBP1-47386) that showed depleted CD44 antigen in the UB can be seen. Image, protocol and testing courtesy of YCharOS Inc. (ycharos.com).](http://images.novusbio.com/fullsize/CD44-Antibody-8E2F3-BSA-Free-Immunoprecipitation-NBP1-47386-img0020.jpg)
![Western Blot: HIF-1 alpha Antibody [NB100-654] - Effects of in vitro hypoxia on the expression of mouse HIF-1 alpha in HIF-1 alpha+/- and HIF-1 alpha+/+ astrocytes. Confluent astrocyte monolayers of both cell types were exposed to a 6 h in vitro hypoxia. HIF-1 alpha mRNA expression was determined by RT-PCR as described in Materials and Methods. Each bar represents the mean +/- SD of relative density/volumes of the bands on film negatives from at least three experiments. Asterisks and number sign indicate significant difference (p < 0.01; one-way ANOVA, followed by multiple comparisons among means). Image collected and cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-4-12), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Western-Blot-NB100-654-img0009.jpg "<b>Biological Strategies Validation, Genetic Strategies Validation and Orthogonal Strategies Validation.</b>Western Blot: HIF-1 alpha Antibody [NB100-654] - Effects of in vitro hypoxia on the expression of mouse HIF-1 alpha in HIF-1 alpha+/- and HIF-1 alpha+/+ astrocytes. Confluent astrocyte monolayers of both cell types were exposed to a 6 h in vitro hypoxia. HIF-1 alpha mRNA expression was determined by RT-PCR as described in Materials and Methods. Each bar represents the mean +/- SD of relative density/volumes of the bands on film negatives from at least three experiments. Asterisks and number sign indicate significant difference (p < 0.01; one-way ANOVA, followed by multiple comparisons among means). Image collected and cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-4-12), licensed under a CC-BY license.")
![<b>Biological Strategies Validation, Genetic Strategies Validation and Orthogonal Strategies Validation.</b>Western Blot: HIF-1 alpha Antibody [NB100-654] - Effects of CoCl2 treatment on HIF-1 alpha expression in mouse astrocytes. Western blots using nuclear proteins show that both hypoxia (H) and CoCl2 (Co) up-regulated HIF-1 alpha protein in HIF-1 alpha+/+ and HIF-1 alpha+/- cells. There was no HIF-1 alpha protein detected in control cells. Image collected and cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-4-12), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Western-Blot-NB100-654-img0008.jpg)
![Immunohistochemistry-Paraffin: HIF-1 alpha Antibody [NB100-654] - IHC analysis of a formalin-fixed paraffin-embedded tissue section of human endometrium carcinoma AN3CA cell line based xenograft using rabbit polyclonal HIF-1 alpha antibody NB100-654 at 1:300 dilution. The signal was developed using HRP-labelled secondary antibody and DAB reagent, and the section was further counterstained using hematoxylin. The tested section depicted mainly a diffused cytoplasmic staining but there were some cells which showed nuclear signal also (representing hypoxic cells).](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Immunohistochemistry-Paraffin-NB100-654-img0006.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: HIF-1 alpha Antibody [NB100-654] - HIF1-alpha analysis using NB100-654. Image submitted from verified customer review.](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Western-Blot-NB100-654-img0007.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: HIF-1 alpha Antibody [NB100-654] - Detection of HIF-1 alpha in cobalt chloride treated/untreated COS-7 nuclear extracts using NB100-654.](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Western-Blot-NB100-654-img0003.jpg)
![Simple Western: HIF-1 alpha Antibody [NB100-654] - Simple Western lane view shows a specific band for HIF-1 alpha in 0.5 mg/ml of Hypoxic HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Simple-Western-NB100-654-img0005.jpg)
![Gel Super Shift Assays: HIF-1 alpha Antibody [NB100-654] - Mouse HIF-1 alpha+/+ and HIF-1 alpha+/- cells were exposed to hypoxia or 125 uM CoCl2 for 6 h, nuclear extracts were then prepared and EMSA carried out. HIF-1 isolated from hypoxia or CoCl2-treated cells bound to the wild-type probe (lanes #1-6) but not to the mutant probe (lanes #7-12). HIF-1/DNA complex was detected in hypoxia (H)-or CoCl2 (Co)-treated cells (lanes #2, 3, 5, 6) but not in control (C) cells (lanes #1, 4). More complex (darker band) was seen in hypoxia-or CoCl2-treated HIF-1 alpha+/+ cells (lanes #2, 3) than that in hypoxia-or CoCl2-treated HIF-1 alpha+/- cells (lanes #5, 6). Supershift assay showed that the HIF-1/DNA complex was shifted up in the presence of wild-type (wt) oligo probe and 4 ug HIF-1 alpha antiboby (lanes #13 & 14). Image collected and cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-4-12), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Gel-Super-Shift-Assays-NB100-654-img0011.jpg)
![Western Blot: HIF-1 alpha Antibody - BSA Free [NB100-654] - Effects of CoCl2 treatment on HIF-1 alpha expression in mouse astrocytes. (A) The cells were incubated in the presence or absence of 125 μM CoCl2 for 6 hr. HIF-1 alpha mRNA expression was determined by RT-PCR. Each bar represents the mean ± SD of relative density/volumes of the bands on film negatives from at least three experiments. Asterisk & number sign indicate significant difference compared to relevant controls (p < 0.01; one-way ANOVA, followed by multiple comparisons among means). (B) Western blots using nuclear proteins show that both hypoxia (H) & CoCl2 (Co) up-regulated HIF-1 alpha protein in HIF-1 alpha +/+ & HIF-1 alpha +/- cells. There was no HIF-1 alpha protein detected in control cells (C). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/17474992), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-654_rabbit-polyclonal-hif-1-alpha-antibody-31020241529191.jpg)
![Western Blot: HIF-1 alpha Antibody - BSA Free [NB100-654] - Aberrant HIF1 alpha expression in PDAC cancer associated fibroblastsA. The level of MCT4 was determined in the indicated established pancreatic cancer cell lines & CAF cultures by immunoblotting. B. The level of MCT1 was determined in the indicated established pancreatic cancer cell lines & CAF cultures by immunoblotting. C. HIF alpha & MCT4 levels were determined by immunoblotting following the knockdown of HIF1 alpha with RNAi or the induction of hypoxia through the use of CoCl2. D. The stability of HIF1 alpha was evaluated in CAFs following treatment with cycloheximide. E. HIF1 alpha was detected by immunoblotting in the presence of cycloheximide in the absence or presence of the proteasome inhibitor MG132. F. HIF1 alpha protein levels were determined in the absence & presence of DMOG. G. RNA levels of the indicated genes as determined by microarray analyses (**p < 0.01 for tumor cell line vs. CAF). H. MG132 was used to interrogate the synthetic rate of HIF1 alpha protein in the indicated cell lines. I. The expression of HIF1 alpha target genes was evaluated in the indicated cell lines by microarray analysis (**p < 0.01 for tumor cell vs. CAF). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27623078), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-654_rabbit-polyclonal-hif-1-alpha-antibody-31020241553714.jpg)
![Western Blot: HIF-1 alpha Antibody - BSA Free [NB100-654] - Aberrant HIF1 alpha expression in PDAC cancer associated fibroblastsA. The level of MCT4 was determined in the indicated established pancreatic cancer cell lines & CAF cultures by immunoblotting. B. The level of MCT1 was determined in the indicated established pancreatic cancer cell lines & CAF cultures by immunoblotting. C. HIF alpha & MCT4 levels were determined by immunoblotting following the knockdown of HIF1 alpha with RNAi or the induction of hypoxia through the use of CoCl2. D. The stability of HIF1 alpha was evaluated in CAFs following treatment with cycloheximide. E. HIF1 alpha was detected by immunoblotting in the presence of cycloheximide in the absence or presence of the proteasome inhibitor MG132. F. HIF1 alpha protein levels were determined in the absence & presence of DMOG. G. RNA levels of the indicated genes as determined by microarray analyses (**p < 0.01 for tumor cell line vs. CAF). H. MG132 was used to interrogate the synthetic rate of HIF1 alpha protein in the indicated cell lines. I. The expression of HIF1 alpha target genes was evaluated in the indicated cell lines by microarray analysis (**p < 0.01 for tumor cell vs. CAF). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27623078), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-654_rabbit-polyclonal-hif-1-alpha-antibody-31020241682154.jpg)
![Western Blot: HIF-1 alpha Antibody - BSA Free [NB100-654] - Aberrant HIF1 alpha expression in PDAC cancer associated fibroblastsA. The level of MCT4 was determined in the indicated established pancreatic cancer cell lines & CAF cultures by immunoblotting. B. The level of MCT1 was determined in the indicated established pancreatic cancer cell lines & CAF cultures by immunoblotting. C. HIF alpha & MCT4 levels were determined by immunoblotting following the knockdown of HIF1 alpha with RNAi or the induction of hypoxia through the use of CoCl2. D. The stability of HIF1 alpha was evaluated in CAFs following treatment with cycloheximide. E. HIF1 alpha was detected by immunoblotting in the presence of cycloheximide in the absence or presence of the proteasome inhibitor MG132. F. HIF1 alpha protein levels were determined in the absence & presence of DMOG. G. RNA levels of the indicated genes as determined by microarray analyses (**p < 0.01 for tumor cell line vs. CAF). H. MG132 was used to interrogate the synthetic rate of HIF1 alpha protein in the indicated cell lines. I. The expression of HIF1 alpha target genes was evaluated in the indicated cell lines by microarray analysis (**p < 0.01 for tumor cell vs. CAF). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27623078), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-654_rabbit-polyclonal-hif-1-alpha-antibody-310202415523946.jpg)
![Western Blot: HIF-1 alpha Antibody - BSA Free [NB100-654] - Aberrant HIF1 alpha expression in PDAC cancer associated fibroblastsA. The level of MCT4 was determined in the indicated established pancreatic cancer cell lines & CAF cultures by immunoblotting. B. The level of MCT1 was determined in the indicated established pancreatic cancer cell lines & CAF cultures by immunoblotting. C. HIF alpha & MCT4 levels were determined by immunoblotting following the knockdown of HIF1 alpha with RNAi or the induction of hypoxia through the use of CoCl2. D. The stability of HIF1 alpha was evaluated in CAFs following treatment with cycloheximide. E. HIF1 alpha was detected by immunoblotting in the presence of cycloheximide in the absence or presence of the proteasome inhibitor MG132. F. HIF1 alpha protein levels were determined in the absence & presence of DMOG. G. RNA levels of the indicated genes as determined by microarray analyses (**p < 0.01 for tumor cell line vs. CAF). H. MG132 was used to interrogate the synthetic rate of HIF1 alpha protein in the indicated cell lines. I. The expression of HIF1 alpha target genes was evaluated in the indicated cell lines by microarray analysis (**p < 0.01 for tumor cell vs. CAF). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27623078), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-654_rabbit-polyclonal-hif-1-alpha-antibody-31020241553515.jpg)
![Western Blot: LAP (TGF-beta 1) Antibody (7F6) [NBP2-22114] - Western blot analysis using TGF beta 1 mAb against human LAP (TGF-beta 1) recombinant protein. (Expected MW is 41 kDa)](http://images.novusbio.com/fullsize/TGF-beta-1-Antibody-7F6-Western-Blot-NBP2-22114-img0002.jpg "Western Blot: LAP (TGF-beta 1) Antibody (7F6) [NBP2-22114] - Western blot analysis using TGF beta 1 mAb against human LAP (TGF-beta 1) recombinant protein. (Expected MW is 41 kDa)")
![Immunohistochemistry-Paraffin: LAP (TGF-beta 1) Antibody (7F6) [NBP2-22114] - Immunohistochemical analysis of paraffin-embedded lymphoid tissue tissues using LAP (TGF-beta 1) mouse mAb with DAB staining.](http://images.novusbio.com/fullsize/TGF-beta-1-Antibody-7F6-Immunohistochemistry-Paraffin-NBP2-22114-img0005.jpg)
![Flow Cytometry: LAP (TGF-beta 1) Antibody (7F6) [NBP2-22114] - Flow cytometric analysis of A549 cells using LAP (TGF-beta 1) mouse mAb (green) and negative control (red).](http://images.novusbio.com/fullsize/TGF-beta-1-Antibody-7F6-Flow-Cytometry-NBP2-22114-img0003.jpg)
![Western Blot: LAP (TGF-beta 1) Antibody (7F6) [NBP2-22114] - Western blot analysis of human stomach tissue (A) and human small intestine tissue (B) using TGF beta 1 antibody (NBP2-22114) at 2 ug/ml.](http://images.novusbio.com/fullsize/TGF-beta-1-Antibody-7F6-Western-Blot-NBP2-22114-img0007.jpg)
![Immunohistochemistry-Paraffin: LAP (TGF-beta 1) Antibody (7F6) [NBP2-22114] - Human tonsil. Image from verified customer review.](http://images.novusbio.com/fullsize/TGF-beta-1-Antibody-7F6-Immunohistochemistry-Paraffin-NBP2-22114-img0006.jpg)
![Immunohistochemistry-Paraffin: LAP (TGF-beta 1) Antibody (7F6) [NBP2-22114] - Immunohistochemical analysis of paraffin-embedded lung cancer tissues using LAP (TGF-beta 1) mouse mAb with DAB staining.](http://images.novusbio.com/fullsize/TGF-beta-1-Antibody-7F6-Immunohistochemistry-Paraffin-NBP2-22114-img0004.jpg)
![ELISA: LAP (TGF-beta 1) Antibody (7F6) [NBP2-22114] - Red: Control Antigen (100ng); Purple: Antigen (10ng); Green: Antigen (50ng); Blue: Antigen (100ng).](http://images.novusbio.com/fullsize/TGF-beta-1-Antibody-7F6-ELISA-NBP2-22114-img0001.jpg)
![Immunohistochemistry-Paraffin: CD68/SR-D1 Antibody (ED1) [NB600-985] - Cynomolgus monkey spleen. IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-ED1-Immunohistochemistry-Paraffin-NB600-985-img0012.jpg "Immunohistochemistry-Paraffin: CD68/SR-D1 Antibody (ED1) [NB600-985] - Cynomolgus monkey spleen. IHC-P image submitted by a verified customer review.")
![Flow Cytometry: CD68/SR-D1 Antibody (ED1) [NB600-985] - Staining of rat peritoneal macrophages cells.](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-ED1-Flow-Cytometry-NB600-985-img0008.jpg)
![Flow Cytometry: CD68/SR-D1 Antibody (ED1) [NB600-985] - Staining of rat peritoneal macrophages.](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-ED1-Flow-Cytometry-NB600-985-img0009.jpg)
![Flow Cytometry: CD68/SR-D1 Antibody (ED1) [NB600-985] - Staining of rat peritoneal macrophages](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-ED1-Flow-Cytometry-NB600-985-img0010.jpg)
![Immunohistochemistry-Frozen: CD68/SR-D1 Antibody (ED1) [NB600-985] - The feline macrophage containing section was incubated with the antibody at 1:50 and the section was further stained with Alexa secondary antibody. Image was captured with an epifluorescence microscope. IHC-Fr image submitted by a verified customer review.](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-ED1-Immunohistochemistry-Frozen-NB600-985-img0015.jpg)
![Flow Cytometry: CD68/SR-D1 Antibody (ED1) [NB600-985] - Decidual Macrophages were analyzed with a BD LSRFortessa. Antibody was diluted 1:100 in staining buffer before use. Isotype control is in Red. Sample with NB600-985AF700 is in Blue. Image from the Alexa Fluor 700 version of this antibody.](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-ED1-Flow-Cytometry-NB600-985-img0016.jpg)
![Immunohistochemistry-Paraffin: CD68/SR-D1 Antibody (ED1) [NB600-985] - Staining of rat liver](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-ED1-Immunohistochemistry-Paraffin-NB600-985-img0011.jpg)
![Flow Cytometry: CD68/SR-D1 Antibody (ED1) [NB600-985] - Staining of rat peritoneal macrophages cells.](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-ED1-Flow-Cytometry-NB600-985-img0007.jpg)
![Flow Cytometry: CD68/SR-D1 Antibody (ED1) [NB600-985] - An intracellular stain was performed on Jurkat cells with BAK antibody (8B4) NBP1-74026PE (blue) and a matched isotype control NB600-985PE (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to phycoerythrin. Image using the PE form of this antibody.](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-ED1-Flow-Cytometry-NB600-985-img0013.jpg)
![Flow (Intracellular): CD68/SR-D1 Antibody (ED1) [NB600-985] - An intracellular stain was performed on U-937 cells with CD68/SR-D1 Antibody (ED1) NB600-985PE (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to phycoerythrin.](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-ED1-Flow-Intracellular-NB600-985-img0014.jpg)
![Western Blot: ICAM-1/CD54 Antibody (1A29) [NBP2-22541] - Western blot analysis of MDA-MB-231 cells transfected with/without an IL-8 silencer RNA (siIL-8) to evaluate the expression of MUC-1, VCAM-1 (NBP1-28404), and ICAM-1 (NBP2-22541). GAPDH load control was reused for illustrative purposes. Image collected and cropped by CiteAb from the following publication (frontiersin.org/article/10.3389/fimmu.2018.01767/full), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/ICAM-1-CD54-Antibody-1A29-Western-Blot-NBP2-22541-img0015.jpg "<b>Biological Strategies Validation. </b>Western Blot: ICAM-1/CD54 Antibody (1A29) [NBP2-22541] - Western blot analysis of MDA-MB-231 cells transfected with/without an IL-8 silencer RNA (siIL-8) to evaluate the expression of MUC-1, VCAM-1 (NBP1-28404), and ICAM-1 (NBP2-22541). GAPDH load control was reused for illustrative purposes. Image collected and cropped by CiteAb from the following publication (frontiersin.org/article/10.3389/fimmu.2018.01767/full), licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Immunohistochemistry-Frozen: ICAM-1/CD54 Antibody (1A29) [NBP2-22541] - Staining of frozen rat spleen with Mouse anti Rat CD54.](http://images.novusbio.com/fullsize/ICAM-1-CD54-Antibody-1A29-Immunohistochemistry-Frozen-NBP2-22541-img0011.jpg)
![Flow Cytometry: ICAM-1/CD54 Antibody (1A29) [NBP2-22541] - Analysis of CD54 in C6 cells (green) compared to an isotype control (blue).](http://images.novusbio.com/fullsize/ICAM-1-CD54-Antibody-1A29-Flow-Cytometry-NBP2-22541-img0014.jpg)
![Immunohistochemistry-Paraffin: ICAM-1/CD54 Antibody (1A29) [NBP2-22541] - Normal biopsies of deparaffinized Mouse kidney tissue.](http://images.novusbio.com/fullsize/ICAM-1-CD54-Antibody-1A29-Immunohistochemistry-Paraffin-NBP2-22541-img0001.jpg)
![Immunohistochemistry: ICAM-1/CD54 Antibody (1A29) [NBP2-22541] - Normal biopsies of deparaffinized Mouse lung tissue.](http://images.novusbio.com/fullsize/ICAM-1-CD54-Antibody-1A29-Immunohistochemistry-NBP2-22541-img0002.jpg)
![Immunohistochemistry-Paraffin: ICAM-1/CD54 Antibody (1A29) [NBP2-22541] - Normal biopsies of deparaffinized Mouse spleen tissue.](http://images.novusbio.com/fullsize/ICAM-1-CD54-Antibody-1A29-Immunohistochemistry-Paraffin-NBP2-22541-img0003.jpg)
![Flow Cytometry: ICAM-1/CD54 Antibody (1A29) [NBP2-22541] - Staining of stimulated rat spleen cells with mouse anti-rat CD54 (Alexa488).](http://images.novusbio.com/fullsize/ICAM-1-CD54-Antibody-1A29-Flow-Cytometry-NBP2-22541-img0010.jpg)
![Flow Cytometry: ICAM-1/CD54 Antibody (1A29) [NBP2-22541] - Analysis of CD54 in Ramos cells (green) compared to an isotype control (blue).](http://images.novusbio.com/fullsize/ICAM-1-CD54-Antibody-1A29-Flow-Cytometry-NBP2-22541-img0012.jpg)
![Flow Cytometry: ICAM-1/CD54 Antibody (1A29) [NBP2-22541] - Analysis of CD54 in Raji cells (green) compared to an isotype control (blue).](http://images.novusbio.com/fullsize/ICAM-1-CD54-Antibody-1A29-Flow-Cytometry-NBP2-22541-img0013.jpg)
![Western Blot: ICAM-1/CD54 Antibody (1A29) [NBP2-22541] - Normalized gene & protein expression of ICAM-1. (A) qPCR results indicated no change in mRNA expression of ICAM-1 at 24 h post-overpressure but a significant increase at 48 h as compared to sham. (B) Subsequent Western blot results confirmed elevated ICAM-1 protein levels at 48 h compared to sham. *p < 0.05, Data are represented as mean ± SEM, gene: n = 7–9/group, protein: n = 8–9/group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30853931), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-22541_mouse-monoclonal-icam-1-cd54-antibody-1a29-31020241536370.jpg)
![Western Blot: ICAM-1/CD54 Antibody (1A29) [NBP2-22541] - Fractionated, compared to single exposure, radiation more profoundly enhanced ICAM-1 expression. Representative (3 independent experiments) Western blot analysis & quantification of ICAM-1 levels in whole-cell lysates from nonirradiated (sham) & irradiated HUVECs 4 h & 24 h after exposure to (a) either five fractions of 2 Gy (5 × 2 Gy) or single exposure to 10 Gy & (b) either five fractions of 2.5 Gy (5 × 2.5 Gy) or single exposure to 12.5 Gy. Fractions delivered at 24-h intervals. beta -actin served as a loading control. c Ectopic expression of ICAM-1 after exposure to 0 Gy, five fractions of 2 Gy, or 10 Gy, as measured by flow cytometry (n = 3). d NF-kappa B activation after 4 h of exposure to 0 Gy, five fractions of 2 Gy, or 10 Gy (n = 2). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32382091), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-22541_mouse-monoclonal-icam-1-cd54-antibody-1a29-31020241533490.jpg)
![Western Blot: ICAM-1/CD54 Antibody (1A29) [NBP2-22541] - Fractionated thoracic irradiation suppressed KLF2 & enhanced ICAM-1 levels in the lung. Quantification of KLF2 (a) & ICAM-1 (b) protein levels & representative Western blot analysis (c) in the lung tissue of mice (n = 6) at 24 h following 5 fractions of 4 Gy at 24 h intervals or single exposure to 20 Gy. beta -actin served as a loading control. KLF2 immunostaining in the lung tissue samples of sham irradiated (d), irradiated (e), & quantitation (f) at 24 h after exposure to 5 fractions of 4 Gy at 24 h intervals or single exposure to 20 Gy. ICAM-1 immunostaining in the lung tissue samples of sham irradiated (g), or irradiated (h), & quantitation (i) at 24 h after exposure to 5 fractions of 4 Gy at 24 h intervals or single exposure to 20 Gy. (n, number of independent experiments performed; a, significant statistical difference between nonirradiated & irradiated groups; b, significant statistical difference between fractionated irradiation & single exposure; *p < 0.05; **p < 0.01; ***p < 0.001). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32382091), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-22541_mouse-monoclonal-icam-1-cd54-antibody-1a29-31020241611356.jpg)
![Flow Cytometry: CD90/Thy1 Antibody (OX-7) [NB100-65543] - Staining of rat thymus.](http://images.novusbio.com/fullsize/CD90-Thy1-Antibody-OX-7-Flow-Cytometry-NB100-65543-img0006.jpg "Flow Cytometry: CD90/Thy1 Antibody (OX-7) [NB100-65543] - Staining of rat thymus.")
![Flow Cytometry: CD90/Thy1 Antibody (OX-7) [NB100-65543] - Staining of rat thymus with MOUSE ANTI RAT CD90 (THY 1.1).](http://images.novusbio.com/fullsize/CD90-Thy1-Antibody-OX-7-Flow-Cytometry-NB100-65543-img0001.jpg)
![Flow Cytometry: CD90/Thy1 Antibody (OX-7) [NB100-65543] - Staining of rat thymocytes.](http://images.novusbio.com/fullsize/CD90-Thy1-Antibody-OX-7-Flow-Cytometry-NB100-65543-img0002.jpg)
![Flow Cytometry: CD90/Thy1 Antibody (OX-7) [NB100-65543] - Staining of rat thymocytes.](http://images.novusbio.com/fullsize/CD90-Thy1-Antibody-OX-7-Flow-Cytometry-NB100-65543-img0003.jpg)
![Flow Cytometry: CD90/Thy1 Antibody (OX-7) [NB100-65543] - Staining of rat thymus cell.](http://images.novusbio.com/fullsize/CD90-Thy1-Antibody-OX-7-Flow-Cytometry-NB100-65543-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: CTGF/CCN2 Antibody [NB100-724] - CTGF antibody was tested in U2OS cells with Dylight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red).](http://images.novusbio.com/fullsize/CTGF-CCN2-Antibody-Immunocytochemistry-Immunofluorescence-NB100-724-img0004.jpg "Immunocytochemistry/Immunofluorescence: CTGF/CCN2 Antibody [NB100-724] - CTGF antibody was tested in U2OS cells with Dylight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red).")
![Immunohistochemistry-Paraffin: CTGF/CCN2 Antibody [NB100-724] - Analysis of a FFPE tissue section of human lymph node using 1:200 dilution of CTGF/CCN2 antibody (NB100-724). The staining was developed using HRP labeled anti-rabbit secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin.](http://images.novusbio.com/fullsize/CTGF-CCN2-Antibody-Immunohistochemistry-Paraffin-NB100-724-img0005.jpg)
![Immunocytochemistry/ Immunofluorescence: CTGF/CCN2 Antibody [NB100-724] - Analysis of astrocyte reactivity, the cytoskeleton & migration rate following treatment with TGF-beta 2 & CCN2/CTGF. (A) GFAP immunoreactivity (green) is increased in murine ON astrocytes following TGF-beta 2 & CCN2/CTGF treatment. Nuclei are stained with Dapi (blue) (B) Western Blot experiments analyses of alpha -actinin protein synthesis in murine ON astrocytes after the treatment with 1 ng/ml TGF-beta 2, 50 ng/ml CCN2/CTGF & 100 ng/ml CCN2/CTGF for 24 h. Densitometric analyses of Western Blot analyses shows the significant increase in alpha -actinin protein synthesis. Mean value of untreated cells (control) was set at 1. GAPDH was used to normalize protein intensity (n = 4; 50 ng CCN2/CTGF: *p = 0.029; 100 ng CCN2/CTGF: *p = 0.015; unpaired two-tailed t-test). (C) Scratch assay analyses show a significant increased migration rate for murine ON astrocytes after the treatment with ng/ml TGF-beta 2, 50 ng/ml CCN2/CTGF & 100 ng/ml CCN2/CTGF for 12 h. Mean value of migration rate of control cells was set to 100% (control: n = 15; TGF-beta 2: n = 12, **p = 0.008; 50 ng/ml CCN2/CTGF: n = 10, *p = 0.001; 100 ng/ml CCN2/CTGF: n = 4, **p = 0.0001). Data represented as mean ± SD. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35493079), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-724_rabbit-polyclonal-ctgf-ccn2-antibody-31020241683912.jpg)
![Immunohistochemistry: CTGF/CCN2 Antibody [NB100-724] - GFAP expression & synthesis in the ON & ONH in a murine glaucoma model. (A) GFAP immunoreactivity in the glial lamina of 1-month (green, upper panel) & 2 months (green, middle & lower panel) old beta B1-CTGF1 mice compared to WT controls. Immunoreactivity of GFAP not altered in 1-month old TG & WT animals (green, upper panel). 2 month old beta B1-CTGF1 mice showed an increased GFAP immunoreactivity compared to WT control (green, middle panel). Lower panel shows a magnified detail of the middle panel. Nuclei are stained w/ Dapi (blue). (B) Schmatic illustration of the optic nerve. A depicts region in the glial lamina where cross sections obtained. ONH (unmyelinated part) & ON (myelinated part) used for molecular analysis. (C) Quantification of immunohistochemical staining of GFAP in the glial lamina is not altered in 1 month old TG & WT animals (WT: n = 5; TG: n = 4). GFAP immunoreactivity is increased in 2 month old TG animals compared to WT littermates (WT: n = 10, TG: n = 13; *p = 0.039; two-tailed t-test compared to oretical mean of 1 (normalized control)). Mean value of WT animals (control) set at 1. (D) RT-PCR analyses revealed no alteration in the Gfap mRNA expression in the ON of 1-month (WT: n = 7; TG: n = 5) & 2 month old beta B1-CTGF1 mice (WT: n = 15; TG: n = 16) compared to WT controls. In the ONH the Gfap mRNA expression is increased in the 2 month old TG compared to WT animals (WT: n = 6, TG: n = 5; *p = 0.04). The mRNA expression of Gfap is not altered in 1 month old animals (WT: n = 6, TG: n = 5). Mean value of WT animals (control) set at 1. RPL32 used to normalize mRNA expression. Data represented as mean ± SEM. PRL, Prelaminar region; PSL, Postlaminar region; ON, optic nerve; ONH, optic nerve head. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35493079), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-724_rabbit-polyclonal-ctgf-ccn2-antibody-310202415523931.jpg)
![Immunohistochemistry: CTGF/CCN2 Antibody [NB100-724] - GFAP expression & synthesis in the ON & ONH in a murine glaucoma model. (A) GFAP immunoreactivity in the glial lamina of 1-month (green, upper panel) & 2 months (green, middle & lower panel) old beta B1-CTGF1 mice compared to WT controls. Immunoreactivity of GFAP not altered in 1-month old TG & WT animals (green, upper panel). 2 month old beta B1-CTGF1 mice showed an increased GFAP immunoreactivity compared to WT control (green, middle panel). Lower panel shows a magnified detail of the middle panel. Nuclei are stained w/ Dapi (blue). (B) Schmatic illustration of the optic nerve. A depicts region in the glial lamina where cross sections obtained. ONH (unmyelinated part) & ON (myelinated part) used for molecular analysis. (C) Quantification of immunohistochemical staining of GFAP in the glial lamina is not altered in 1 month old TG & WT animals (WT: n = 5; TG: n = 4). GFAP immunoreactivity is increased in 2 month old TG animals compared to WT littermates (WT: n = 10, TG: n = 13; *p = 0.039; two-tailed t-test compared to oretical mean of 1 (normalized control)). Mean value of WT animals (control) set at 1. (D) RT-PCR analyses revealed no alteration in the Gfap mRNA expression in the ON of 1-month (WT: n = 7; TG: n = 5) & 2 month old beta B1-CTGF1 mice (WT: n = 15; TG: n = 16) compared to WT controls. In the ONH the Gfap mRNA expression is increased in the 2 month old TG compared to WT animals (WT: n = 6, TG: n = 5; *p = 0.04). The mRNA expression of Gfap is not altered in 1 month old animals (WT: n = 6, TG: n = 5). Mean value of WT animals (control) set at 1. RPL32 used to normalize mRNA expression. Data represented as mean ± SEM. PRL, Prelaminar region; PSL, Postlaminar region; ON, optic nerve; ONH, optic nerve head. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35493079), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-724_rabbit-polyclonal-ctgf-ccn2-antibody-310202415535150.jpg)
![Immunocytochemistry/ Immunofluorescence: CTGF/CCN2 Antibody [NB100-724] - Analyses of ECM components in murine ON astrocytes following treatment w/ TGF-beta 2 & CCN2/CTGF. (A) Immunocytochemical staining against fibronectin (green, upper panel) showed a markedly increase following the treatment w/ 1 ng/ml TGF-beta 2 or 50 ng/ml CCN2/CTGF. Immunocytochemical staining against tropoelastin (green, lower panel) showed a pronounced increase after treatment w/ 1 ng/ml TGF-beta 2 or 50 ng/ml CCN2/CTGF. Nuclei stained w/ Dapi (blue). (B) Real-time RT-PCR analyses shows an intense upregulation of collagen 3 alpha 1, tropoelastin & fibronectin mRNA in murine ON astrocytes after treatment w/ 1 ng/ml TGF-beta 2, 50 ng/ml CCN2/CTGF or 100 ng/ml CCN2/CTGF for 24 h compared to untreated control cells (collagen 3 alpha 1: n = 3; TGF-beta 2 ***p = 0.0000004, 50 ngCTGF **p = 0.005, 100ngCTGF **p = 0.008; fibronectin: n = 6, TGF-beta 2 *p = 0.00004, 50 ng CTGF *p = 0.016, 100 ngCTGF *p = 0.05; elastin: n = 5, TGF-beta 2 *p = 0.026, 50 ng CTGF *0.04, 100 ng CTGF *p = 0.03). mRNA expression normalized to Gnb2l & mean value of control cells set at 1. (C) Western Blot analysis show an increase in protein synthesis of collagen 3 alpha 1, elastin & fibronectin in murine ON astrocytes after treatment w/ 1 ng/ml TGF-beta 2, 50 ng/ml CCN2/CTGF or 100 ng/ml CCN2/CTGF for 24 h compared to untreated control cells (collagen 3 alpha 1: n = 3, TGF-beta 2 *p = 0.03, 100 ngCTGF **p = 0.009; fibronectin: n = 5, **p = 0.005, 50 ngCTGF **p = 0.006, 100 ng CTGF *p = 0.02; tropoelastin: n = 5, TGF-beta 2 ***p = 0.0004, 50 ngCTGF **p = 0.002, 100 ngCTGF ***p = 0.00001). GAPDH & alpha -tubulin used to normalize protein synthesis & mean value of control cells set at 1. Right panel shows representative Western Blots for all three proteins. Data represented as mean ± SD. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35493079), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-724_rabbit-polyclonal-ctgf-ccn2-antibody-310202415532092.jpg)
![Immunocytochemistry/ Immunofluorescence: CTGF/CCN2 Antibody [NB100-724] - Increasing substratum stiffness causes alterations in murine ON astrocyte reactivity, actin cytoskeleton & CCN2/CTGF level. (A) Filamentous actin labeled by phalloidin (red, upper panel) is increased when murine ON astrocytes were cultured on substrates with higher stiffness (30 kPa, 60 kPa) compared to softer control (10 kPa). Increasing substratum stiffness leads to an enhanced formation of actin stress fibers. Immunoreactivity of CCN2/CTGF (green, middle panel) is markedly increased when murine ON astrocytes were grown on substrates with higher stiffness (30, 60 kPa) compared to softer control (10 kPa). Murine ON astrocytes show an enhanced GFAP protein synthesis (green, lower panel) when cultured on 30 or 60 kPa compared to 10 kPa. Nuclei were stained with Dapi (blue). (B) CCN2/CTGF protein synthesis is significantly increased in murine ON astrocytes grown on 60 kPa compared to 10 kPa (10 kPa: n = 5; 30 kPa: n = 5; 60 kPa: n = 5; *p = 0.04; unpaired two-tailed t-test). (C) Protein synthesis of GFAP (10 kPa: n = 6; 30 kPa: n = 6, **p = 0.005; 60 kPa: n = 4, *p = 0.04; unpaired two-tailed t-test) show an enhanced reactivity of murine ON astrocytes cultured on 30 kPa or 60 kPa compared to 10 kPa control. (D) Vimentin protein synthesis is significantly increased in murine ON astrocytes cultured on 60 kPa compared to 10 kPa (10 kPa: n = 4; 30 kPa: n = 4; 60 kPa: n = 3 ***p = 0.00002). Protein synthesis was normalized to alpha -tubulin & mean value of control (10 kPa) was set at 1. Data represented as mean ± SEM. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35493079), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-724_rabbit-polyclonal-ctgf-ccn2-antibody-31020241612698.jpg)
![Western Blot: LYVE-1 Antibody [NB100-725] - Western Blot: [NB100-725] - Total protein from human stomach, lymph node and placenta was separated on a 7.5% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 1.0 ug/ml anti-LYVE1 in 1% milk, and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Western-Blot-NB100-725-img0027.jpg "Western Blot: LYVE-1 Antibody [NB100-725] - Western Blot: [NB100-725] - Total protein from human stomach, lymph node and placenta was separated on a 7.5% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 1.0 ug/ml anti-LYVE1 in 1% milk, and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.")
![Immunohistochemistry-Paraffin: LYVE-1 Antibody [NB100-725] - Analysis using the DyLight 488 conjugate of NB100-725. Staining of LYVE1 in paraffin embedded MDA-MB-231 breast cancer orthotopic transplantation tissue. Image courtesy of product review submitted by Luana Schito.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Immunohistochemistry-Paraffin-NB100-725-img0028.jpg)
![Immunohistochemistry: LYVE-1 Antibody [NB100-725] - Detection of LYVE1 in endothelial cells of human lung blood vessels using NB100-725. Note presence of RBCs within vessel lumen.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Immunohistochemistry-NB100-725-img0011.jpg)
![Flow Cytometry: LYVE-1 Antibody [NB100-725] - Analysis using the DyLight 488 conjugate of NB100-725. Unlabeled control with labeled samples of cells dissociated mechanically and enzymatically from human skin. Image provided via product review by Patricia Redondo.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Flow-Cytometry-NB100-725-img0024.jpg)
![Western Blot: LYVE-1 Antibody [NB100-725] - Analysis of extracts from A549 cells using LYVE1 antibody (NB100-725, 1:100). Image from verified customer review.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Western-Blot-NB100-725-img0018.jpg)
![Flow Cytometry: LYVE-1 Antibody [NB100-725] - LYVE1 antibody was tested at 1:400 in A549 cells using an Alexa Fluor 488 secondary (shown in green) alongside unstained cells (shown in red).](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Flow-Cytometry-NB100-725-img0016.jpg)
![Flow Cytometry: LYVE-1 Antibody [NB100-725] - An intracellular stain was performed on A549 cells with LYVE-1 Antibody NB100-725 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (SA5-10033, Thermo Fisher).](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Flow-Cytometry-NB100-725-img0031.jpg)
![Immunohistochemistry: LYVE-1 Antibody [NB100-725] - Detection of LYVE1 in endothelial cells of human bladder vasculature using NB100-725.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Immunohistochemistry-NB100-725-img0012.jpg)
![Immunohistochemistry: LYVE-1 Antibody [NB100-725] - Detection of LYVE1 in endothelial cells of human lung blood vessels using NB100-725.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Immunohistochemistry-NB100-725-img0013.jpg)
![Flow Cytometry: LYVE-1 Antibody [NB100-725] - Analysis using the Alexa Fluor (R) 488 conjugate of NB100-725. Staining of LYVE1 in human dissociated skin lyve1+ using AF488 conjugated anti-LYVE1 antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Flow-Cytometry-NB100-725-img0023.jpg)
![Flow Cytometry: LYVE-1 Antibody [NB100-725] - An intracellular stain was performed on A549 cells with LYVE-1 Antibody NB100-725G (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 10 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Dylight 488.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Flow-Cytometry-NB100-725-img0029.jpg)
![Flow Cytometry: LYVE-1 Antibody [NB100-725] - An intracellular stain was performed on K562 cells with LYVE-1 Antibody NB100-725C (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 650.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Flow-Cytometry-NB100-725-img0030.jpg)
![Western Blot: CD44 Antibody [NBP1-31488] - Untreated (-) and treated (+) MDA-MB-231 whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with CD44 antibody. The observed M.W. is different from the predicted size. It is possibly due to post-translational modifications.](http://images.novusbio.com/fullsize/CD44-Antibody-Western-Blot-NBP1-31488-img0031.jpg "<b>Biological Strategies Validation. </b>Western Blot: CD44 Antibody [NBP1-31488] - Untreated (-) and treated (+) MDA-MB-231 whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with CD44 antibody. The observed M.W. is different from the predicted size. It is possibly due to post-translational modifications.")
![<b>Biological Strategies Validation. </b>Western Blot: CD44 Antibody [NBP1-31488] - Untreated (-) and treated (+) HeLa whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with CD44 antibody. The observed M.W. is different from the predicted size. It is possibly due to post-translational modifications.](http://images.novusbio.com/fullsize/CD44-Antibody-Western-Blot-NBP1-31488-img0033.jpg)
![Immunocytochemistry/Immunofluorescence: CD44 Antibody [NBP1-31488] - Analysis of methanol-fixed HeLa, using CD44 antibody (Green) at 1:500 dilution. Alpha-tubulin filaments were labeled with an alpha Tubulin antibody (Red) at 1:2000.](http://images.novusbio.com/fullsize/CD44-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-31488-img0016.jpg)
![Immunohistochemistry-Paraffin: CD44 Antibody [NBP1-31488] - Human cervical carcinoma. CD44 stained by CD44 antibody diluted at 1:500.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.](http://images.novusbio.com/fullsize/CD44-Antibody-Immunohistochemistry-Paraffin-NBP1-31488-img0036.jpg)
![Immunohistochemistry-Paraffin: CD44 Antibody [NBP1-31488] - Human endometrial carcinoma. CD44 antibody diluted at 1:500. Antigen Retrieval: Trilogy™ (EDTA based, pH 8.0) buffer, 15min.](http://images.novusbio.com/fullsize/CD44-Antibody-Immunohistochemistry-Paraffin-NBP1-31488-img0026.jpg)
![Immunohistochemistry-Paraffin: CD44 Antibody [NBP1-31488] - Human pancreatic tumor, using CD44 antibody at 1:100 dilution. Antigen Retrieval: Trilogy™ (EDTA based, pH 8.0) buffer, 15min.](http://images.novusbio.com/fullsize/CD44-Antibody-Immunohistochemistry-Paraffin-NBP1-31488-img0035.jpg)
![Immunocytochemistry/ Immunofluorescence: CD44 Antibody [NBP1-31488] - CD44 antibody detects CD44 protein at cell membrane by immunofluorescent analysis.Sample: A431 cells were fixed in ice-cold MeOH for 5 min.Green: CD44 stained by CD44 antibody (NBP1-31488) diluted at 1:500.Blue: Fluoroshield with DAPI .](http://images.novusbio.com/fullsize/nbp1-31488_rabbit-polyclonal-cd44-antibody-91020242091445.jpg)
![Western Blot: CD44 Antibody [NBP1-31488] - Untreated (-) and treated (+) HeLa whole cell extracts (30 ug) were separated by 10% SDS-PAGE, and the membrane was blotted with CD44 antibody (NBP1-31488) diluted at 1:45000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody, and the signal was developed with Trident ECL plus-Enhanced.](http://images.novusbio.com/fullsize/nbp1-31488_rabbit-polyclonal-cd44-antibody-910202420104431.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: CD44 Antibody [NBP1-31488] - Non-transfected (–) and transfected (+) Wild-type (WT) and G CD44 knockout (KO) HeLa cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with CD44 antibody diluted at 1:7000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.](http://images.novusbio.com/fullsize/nbp1-31488_rabbit-polyclonal-cd44-antibody-1610202419405756.jpg)
![<b>Orthogonal Strategies Validation. </b>Western Blot: CD44 Antibody [NBP1-31488] - Various whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with CD44 antibody diluted at 1:5000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody. Corresponding RNA expression data for the same cell lines are based on Human Protein Atlas program.](http://images.novusbio.com/fullsize/nbp1-31488_rabbit-polyclonal-cd44-antibody-1610202419414564.jpg)
![Western Blot: p38 [p Thr180, p Tyr182] Antibody [NB500-138] - Hela cell lysates that had been treated with UV or untreated (Control) showing specific immunolabeling of the -39 kDa p38 MAPK protein phosphorylated at Thr180/Tyr182.](http://images.novusbio.com/fullsize/p38-[p-Thr180--p-Tyr182]-Antibody-Western-Blot-NB500-138-img0005.jpg "Western Blot: p38 [p Thr180, p Tyr182] Antibody [NB500-138] - Hela cell lysates that had been treated with UV or untreated (Control) showing specific immunolabeling of the -39 kDa p38 MAPK protein phosphorylated at Thr180/Tyr182.")
![Immunohistochemistry-Paraffin: p38 [p Thr180, p Tyr182] Antibody [NB500-138] - Immunostaining of human breast cancer tissue showing p38 when phosphorylated at Thr180/Tyr182 in red.](http://images.novusbio.com/fullsize/p38-[p-Thr180-p-Tyr182]-Antibody-Immunohistochemistry-Paraffin-NB500-138-img0002.jpg)
![Western Blot: p38 [p Thr180, p Tyr182] Antibody [NB500-138] - Western blot of HeLa cell lysates that had been treated with UV or untreated (Control) showing specific immunolabeling of the ~39k p38 MAPK protein phosphorylated at Thr180/Tyr182.](http://images.novusbio.com/fullsize/p38-[p-Thr180-p-Tyr182]-Antibody-Western-Blot-NB500-138-img0001.jpg)
![Western Blot: p38 alpha [p Thr180, p Tyr182] Antibody [NB500-138] - RIP2 is not essential for MAPK pathways in the early ontogenesis. (A) Immunoblot analysis of phospho-p44/42 MAPK, p44/42 MAPK, & p38 MAPK in larvae homogenate from WT & NOD1-1IS−/− zebrafish at 7 days post-fertilization (dpf). (B) Immunoblot analysis of phospho-p44/42 MAPK, p44/42 MAPK, & p38 MAPK in larvae homogenate from WT & RIP2−/− zebrafish at 7 dpf. (C) Immunoblot analysis of Atg5, p62, & LC3b in larvae homogenate from WT & NOD1-1IS−/− zebrafish at 7 dpf. (D) Immunoblot analysis of Atg5, p62, & LC3b in larvae homogenate from WT & RIP2−/− zebrafish at 7 dpf. Western blotting results were quantified using Quantity One software. Data represent the average of two independent experiments. *p < 0.05, **p < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29692779), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb500-138_rabbit-polyclonal-p38-alpha-p-thr180-p-tyr182-antibody-31020241534371.jpg)